File(s) under permanent embargo
The OncoArray Consortium: a network for understanding the genetic architecture of common cancers
METHODS: The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background.
RESULTS: The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis.
CONCLUSIONS: Results from these analyses will enable researchers to identify new susceptibility loci, perform fine mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental and lifestyle related exposures.
IMPACT: Ongoing analyses will shed light on etiology and risk assessment for many types of cancer.
Publication titleCancer Epidemiology, Biomarkers and Prevention
Department/SchoolMenzies Institute for Medical Research
PublisherAmerican Association for Cancer Research
Place of publicationUnited States
Rights statementCopyright 2016 2016 American Association for Cancer Research